TABLE 3.

Viable counts of bifidobacteria in fecal cultures supplemented with NDO and clindamycin

TreatmentBifidobacterial viable counts (log10 CFU ml−1)a
0 h6 h12 h24 h48 h
Control7.8 ± 0.68.2 ± 0.48.2 ± 0.58.1 ± 0.57.6 ± 0.6
NDO treatment group
    FOS7.8 ± 0.68.7 ± 0.38.7 ± 0.48.6 ± 0.47.8 ± 0.7
    GOS7.8 ± 0.68.8 ± 0.38.7 ± 0.58.5 ± 0.46.8 ± 1.5
    Inulin7.9 ± 0.78.6 ± 0.48.6 ± 0.58.3 ± 0.27.6 ± 0.9
    Mean7.8 ± 0.68.7 ± 0.38.7 ± 0.4b8.5 ± 0.37.4 ± 1.0
Clindamycin control8.0 ± 0.66.2 ± 1.36.0 ± 1.25.5 ± 1.15.1 ± 0.9
    Clindamycin + NDO treatment group
    Clindamycin + FOS7.8 ± 0.65.0 ± 0.34.3 ± 0.23.1 ± 0.83.3 ± 0.9
    Clindamycin + GOS7.8 ± 0.65.1 ± 0.54.3 ± 0.33.5 ± 0.73.4 ± 1.0
    Clindamycin + Inulin7.9 ± 0.75.5 ± 1.25.1 ± 1.34.4 ± 1.74.2 ± 1.3
    Mean7.8 ± 0.65.2 ± 0.74.5 ± 0.8c3.6 ± 1.23.6 ± 1.0
  • a Mean ± standard deviation (n = 3).

  • b There was a significant difference between the control and the NDO treatment group as determined by analysis of variance (P ≤ 0.001).

  • c There was a significant difference between the clindamycin control and the group that was treated with clindamycin and NDO (P ≤ 0.05).